So this is a tough one. So biotech and life sciences have longer cycles than than tech. So typically in tech, you're looking at an exit between five to seven years. And in, in biotech you're looking at an exit on a time scale of seven to 10 plus years. Just because there's a lot of technology de-risk and and development that takes significant number of years. And so having been in venture for six years, a lot of my companies are still pre-ex exit stage. But there are many that have done really are tackling really interesting problems. So there's a company that is looking at making cell therapies that are potentially curative and can actually cure cancer or making them more accessible. Because currently it costs about a a million per pop. That is that the pricing the fact that it can't be manufactured to scale makes it inaccessible for patients. And this company is looking at scaling up the manufacturing process, automating it and digitizing it to bring down the costs of manufacturing these therapies. And so that is, for example, one example of a company that's trying to do something very exciting and solve a very interesting challenge. There are other companies that are looking at differentiating stem cells into any other type of cells to develop therapies. There are companies that are looking at delivery as a modality such that you can, you can deliver drugs specifically to the disease tissue without touching the healthy tissue, which is holy grail of medicine. And a lot of the side effects that we see with treatment such as you know, for cancer is because in the process of killing the disease cells, the treatment and the therapies also killing off healthy cells. And so it's problems like these that I have sort of invested in my capacity as an investor. And I get really, really pumped about.